title: [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma].
abstract: We report three radioiodine-resistant patients with metastatic papillary thyroid carcinoma administered docetaxel. Patient 1: Bi-weekly docetaxel was administered to a 67-year-old woman with clavicle, cervical lymph node and lung metastases that had progressed after external irradiation and radioiodine therapy. Stable disease was maintained for 18 months without elevation of serum thyroglobulin. Patient 2: Bi-weekly docetaxel was administered to a 72-year-old man with lung metastases that had progressed after radioiodine therapy. Stable disease was maintained for 14 months. Patient 3: Bi-weekly docetaxel was administered to a 58-year-old woman with lung metastases that had progressed after radioiodine therapy. Stable disease was maintained for 18 months with slight reduction of serum thyroglobulin. In all three patients, doubling time of tumor growth was revealed to be far prolonged after docetaxel administration without distinct adverse events. Since no effective systemic treatment has been established for radioiodine-resistant patients with metastatic papillary thyroid carcinoma,docetaxel therapy was supposed to be a viable alternative for them.
authors.affiliation: Dept. of Breast and Thyroid Surgery, Kawasaki Medical School.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ikeda
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Tanaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonoo
authors.forename: Akiko
authors.initials: A
authors.lastname: Miyake
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Shigeo
authors.initials: S
authors.lastname: Shiiki
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Nakashima
authors.forename: Junichi
authors.initials: J
authors.lastname: Kurebayashi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage*; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013965:Thyroidectomy
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D043823:Taxoids; D000077143:Docetaxel; D013954:Thyroglobulin